Perspectives on the production of pluripotent cells from hematopoietic cells

Dear Editor,

The myth of Prometheus appeared in the writings of Hesiod, a Greek epic poet, who lived at the end of the VIII century BC. According to the myth, Prometheus received a punishment from Zeus, which should last eternally, as he was immortal. Unbreakable chains, forged by Hephaestus, fastened Prometheus to a rock in Caucasus and an imposing eagle would come to eat his liver every day. During the dark night, for which Prometheus longed, the eaten organ would grow back again so that it could be devoured by the bird of prey the very next day. Some tell that the Greek hero Heracles (Roman Hercules) freed Prometheus years later.

It is interesting that tissue regeneration was already mentioned in VIII century BC folklore, in a way that stories showed interest in a possibility that was not yet imagined in the medical science of the era.

The advances in the state of the art related to regeneration have come to a point where scientists are attempting to fully understand the mechanisms and to master techniques of cell reprogramming in order to develop regenerative medicine.

Discussions on the reprogramming of cells started more than 50 years ago and until now questions about which mechanisms are involved remain inadequately answered as do questions on the real applications and safety of the technique. Attempts to revert the lineage commitment of certain animal cells date back to 1960 when Gurdon obtained cells from hematopoietic system cells when CD 45− was acquired from hematopoietic system cells when CD 45− lymphocytes were exposed to an acidic environment (pH 5.7). The results are encouraging and the STAP cells also display the capacity of forming teratomas, an undesirable feature that limits their use in therapy for the time being. Nevertheless, the increase in efficiency and drastically diminished costs, suggest that these cells can be produced in a large scale for future in-depth studies that may culminate in the establishment of cell lineages that make cell therapy feasible. Further studies must be carried out using this technology in order to determine its potential and limitations. Can we expect STAP cells to be used to generate in vitro hematopoietic progenitor cells in the near future?
Conflicts of interest

The authors declare no conflicts of interest.

References


Gustavo Torres de Souza, Camila Maurmann de Souza, Carlos Magno da Costa Maranduba *
Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil

*Corresponding author at: Universidade Federal de Juiz de Fora – UFJF, Rua José Lourenço Kelmer, s/n, Campus Juiz de Fora, 36036-900, Juiz de Fora, MG, Brazil.
E-mail address: carlosmaranduba@yahoo.com.br (C.M. da Costa Maranduba).

Received 2 July 2013
Accepted 17 March 2014
Available online 28 May 2014

http://dx.doi.org/10.1016/j.bjhh.2014.05.009